All News
AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer
(MedPage Today) -- CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant af
Read MoreFrom No Hope to a Potential Cure for a Deadly Blood Cancer
Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.
Read MoreAI and data-driven tools reshape medical device sales enablement
Can you tell us about SmartWinnr? What inspired the idea of developing a specialised sales enablement solution for the medical device industry? At SmartWinnr, we’ve built an AI-Infused Sales Excelle
Read MoreAgentic AI will shift healthcare from being transactional to continuous
What sets Tulu’s AI apart from other chatbot or hospital engagement tools in the market? Unlike traditional healthcare chatbots that are reactive and often limited to static, scripted responses, Tul
Read MoreCoffee and Healthy Aging; FBI Seeks Gender-Affirming Care Tips; More Teens on Wegovy
(MedPage Today) -- Note that some links may require registration or subscription.
Read MorePluvicto pushes earlier in prostate cancer play
Plus more biotech news updates, brought to you by The Readout.
Read MoreAnti-LGBTQ+ incidents related to health care have increased
And more health news updates you need to read today.
Read MoreSTAT+: Pharmalittle: We’re reading about a FDA AI tool, mRNA as a political reject, and more
The FDA rolled out a generative AI tool for speeding regulatory reviews, announcing its launch nearly a month ahead of a June 30 deadline
Read MoreHHS has a new national health IT coordinator
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.
Read MorePARP-ARPI Combo Sets New Standard for Metastatic Hormone-Sensitive Prostate Cancer
(MedPage Today) -- CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progressi
Read More